Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Redhill Biophrma ADR (NQ: RDHL ) 0.3652 -0.0277 (-7.05%) Streaming Delayed Price Updated: 10:43 AM EDT, Jun 20, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Redhill Biophrma ADR RedHill Biopharma Ltd. (NASDAQ: RDHL) is One of Wednesday Morning’s Most Active Stocks November 29, 2023 Via Investor Brand Network RedHill Biopharma Ltd Announces RDHL Opaganib Selected by NIH RNCP For Development February 28, 2023 Via ACCESSWIRE RedHill Biopharma Ltd Announces RedHill's RHB-102 Positive MHRA Meeting & MAA Plan February 16, 2023 Via ACCESSWIRE Aegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for RedHill Biopharma Ltd. (NASDAQ:RDHL) December 07, 2022 Via ACCESSWIRE RedHill Biopharma Ltd Announces Potent Omicron Inhibition with RedHill's Opaganib April 11, 2022 Oral opaganib's reported potent in vitro activity against Omicron adds to previously observed inhibition of Delta and other SARS-CoV-2 variants of concern that cause COVID-19; Testing conducted by The... From RedHill Biopharma Ltd Via AccessWire RedHill Announces Additional Insider Buying December 15, 2021 RALEIGH, NC and TEL-AVIV, ISRAEL / ACCESSWIRE / December 15, 2021 / RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that... From RedHill Biopharma Ltd Via AccessWire Exposures COVID-19 RedHill Biopharma Ltd Announces Concerning Clarithromycin Rx Rates for H. pylori December 09, 2021 RedHill Biopharma: Concerning Rates of Clarithromycin Prescribing for H. pylori, Despite Increasing Antibiotic Resistance, Uncovered in New Digestive Diseases & Sciences Publication Despite increasing... From RedHill Biopharma Ltd Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal Anxious World Waits As Covid Vaccine Makers Address Omicron Variant December 07, 2021 Palm Beach, FL – December 7, 2021 – FinancialNewsMedia.com News Commentary There are many unknowns surrounding the new omicron Covid variant; there are early signs it’s more transmissible, but it’s not... Via FinancialNewsMedia Exposures COVID-19 RedHill Biopharma Ltd - Opaganib MoA Not Impacted by Omicron Mutations December 06, 2021 Unique Mode of Action Opaganib works by targeting the human host cell rather than the virus itself and is therefore not expected to be impacted by spike protein mutations, providing a strong rationale... From RedHill Biopharma Ltd Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal RedHill Biopharma Ltd Announces Talicia: Consistent Efficacy Irrespective of BMI December 02, 2021 RedHill Biopharma Data Published in GastroHep Shows Consistent Efficacy of Talicia Irrespective of Patient BMI High Body Mass Index and obesity are known risk factors for H. Pylori eradication... From RedHill Biopharma Ltd Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal RedHill’s Movantik Added To Medicare Formulary December 01, 2021 RedHill Biopharma's Movantik® Added as Preferred and Unrestricted Brand To Major National Medicare Formulary Serving Millions of Americans Movantik® approved for inclusion as preferred and unrestricted... From RedHill Biopharma Ltd Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal RedHill Reports 3Q/2021 Financial Results November 30, 2021 RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results RedHill Accelerates its Two Advanced COVID-19 Pill Clinical Programs in Light of their Potential Against... From RedHill Biopharma Ltd Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal RedHill Biopharma Ltd Announces RedHill: LPI in Part A of RHB-107 P2/3 COVID Study November 15, 2021 RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients Recruitment completed for Part A of the Phase... From RedHill Biopharma Ltd Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal RedHill Biopharma and South Korea's Kukbo Co. Announce a Strategic Investment of Up To $10 Million in RedHill November 08, 2021 RedHill received the first tranche of $5 million in a private placement of restricted stock priced at $6.04 per ADS, representing a 20% premium based on the 30 trading days' volume weighted average... From RedHill Biopharma Ltd Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal RedHill Biopharma Presents New Talicia(R) and Movantik(R) Data Analyses at ACG 2021 October 25, 2021 Two new analyses evaluate pharmacological and clinical advantages of Talicia® as first-line H. pylori therapy over clarithromycin-based regimens - Two new analyses of Movantik® data evaluate efficacy... From RedHill Biopharma Ltd Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal RedHill Biopharma Announces Insider Buying October 18, 2021 TEL-AVIV, ISRAEL and RALEIGH, NC / ACCESSWIRE / October 18, 2021 / RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that... From RedHill Biopharma Ltd Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal RedHill Biopharma Ltd Announces New U.S. Patent for RedHill's Talicia for H.pylori October 12, 2021 RedHill Biopharma Announces New U.S. Patent Covering Talicia for H. pylori Infection Through 2034 The patent is directed to the Talicia® formulation and pharmaceutical kits for use in the treatment of... From RedHill Biopharma Ltd Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal RedHill Biopharma Ltd Announces Talicia(R) added to Medi-Cal CDL October 06, 2021 RedHill Biopharma's Talicia® added to Medi-Cal Contract Drug List with No Prior Authorization Requirements Addition of Talicia® by Medi-Cal Fee-For-Service (FFS) Contract Drug List (CDL) with no prior... From RedHill Biopharma Ltd Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients October 04, 2021 62% statistically significant reduction in mortality shown for moderately severe COVID-19 patients group treated with opaganib vs. the placebo-controlled arm (7 deaths in the 117-patient opaganib arm... From RedHill Biopharma Ltd Via AccessWire Topics Death Intellectual Property Regulatory Compliance Exposures COVID-19 Death Intellectual Property RHB-107 P2/3 COVID-19 Study South Africa Approval September 13, 2021 RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval The South African Health Products Regulatory... From RedHill Biopharma Ltd Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis September 07, 2021 COVID-19 and long COVID patients are at increased risk of developing kidney damage - Opaganib significantly decreased kidney fibrosis in a preclinical in vivo model - Renal fibrosis is a progressive... From RedHill Biopharma Ltd Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal RedHill Biopharma Ltd Announces New Movantik Analyses at PAINWeek September 07, 2021 RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021 Two new analyses of Movantik® (naloxegol) data evaluated the safety and efficacy of Movantik in a subgroup of patients... From RedHill Biopharma Ltd Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal RedHill to Present at HCW & Cantor Conferences September 02, 2021 RedHill Biopharma to Present at H.C. Wainwright Annual Global Investment and Cantor Global Healthcare Conferences TEL AVIV, ISRAEL and RALEIGH, NC / ACCESSWIRE / September 2, 2021 / RedHill Biopharma... From RedHill Biopharma Ltd Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal RedHill Reports Second Quarter 2021 Results August 26, 2021 - Achieved record quarterly revenues of $21.5 million for Q2/2021, 4.5% increase from Q1/2021 despite challenging market conditions; Cash balance[1] of approximately $71.5 million as of June 30, 2021 -... From RedHill Biopharma Ltd Via AccessWire Topics Intellectual Property Regulatory Compliance Supply Chain Exposures COVID-19 Intellectual Property Legal RedHill Biopharma Ltd Announces RedHill's Opaganib Strong Delta Variant Inhibition August 26, 2021 RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant Opaganib demonstrated strong inhibition of COVID-19 Delta variant in a human bronchial epithelial cells model,... From RedHill Biopharma Ltd Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal RedHill Announces Two New U.S. Patents August 23, 2021 RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn's U.S. patents for opaganib combination for the treatment of Ebola virus disease provides patent... From RedHill Biopharma Ltd Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal RedHill Extends Talicia Commercial Coverage July 20, 2021 RedHill Biopharma Significantly Extends Unrestricted Commercial Coverage for Talicia® with OptumRx Addition of Talicia® by OptumRx significantly extends Commercial patient access to Talicia® through... From RedHill Biopharma Ltd Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal RedHill Biopharma Ltd Announces RedHill Biopharma Announces Last Patient Out July 19, 2021 RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib Patient follow-up completed for the 475-patient global Phase 2/3 study of oral opaganib for severe COVID-19... From RedHill Biopharma Ltd Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal 35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021 May 27, 2021 RALEIGH, NC / ACCESSWIRE / May 27, 2021 / The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be... From MicroCap Rodeo Via AccessWire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.